The Second Affiliated Hospital, Third Military Medical University
Chongqing, Chongqing Municipality, 400037, China
NCT Number: NCT01837433
Efficiency and Safety Study of Short-term Prednisone to Treat Moderate and Severe Subacute Thyroiditis
The investigators hypothesize that less adverse reactions will be observed, comparing with the guidelines recommend. The recurrence rate, adrenal insufficiency, temporary and permanent hypothyroidism aren't significant difference.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Phase 4
Chongqing, Chongqing Municipality, 400037, China
Comparing with the guidelines recommend, short-term (one week)prednisone and nsaids following up next week to treat moderate and severe subacute thyroiditis will be assessed.
The patients in wards will be assessed from temperature,erythrocyte sedimentation rate,C-reactive protein,local pain and goiter.The random treatment will be executed in moderate and severe SAT after informed consent be signed.
Subjects will be monitored once every 2 weeks.If patients complained of pain in their neck or if the erythrocyte sedimentation rate is still high,after discontinuation of prednisone, prednisone treatment will be resumed in moderate and severe subject and non-steroidal anti-inflammatory drugs will be used in mild subject.Anti-ulcer drugs will be administered to all patients.
The endpoint of the study are efficiency and safety of short-term prednisone treating. The investigators will assess adrenal insufficiency (such as anorexia, nausea, vomiting, abdominal pain),steroid withdrawal syndrome, recurrence rate and hypothyroidism. The investigators will observe erythrocyte sedimentation rate,pain,steroid level and thyroid function.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Prednisone 1 week 30mg/day and Celecoxib 400mg in first day, and then 200mg bid in the remaining next week, total 2 weeks.
Other names: Glucocorticoid
Guidelines recommend
Other names: Glucocorticoid
Time frame: 14 days
We will observe change of erythrocyte sedimentation rate from >20mm/h to normal,C-reactive protein,pain and goiter disappear after 14 days.
Time frame: 180 days
The recurrence will be defined:local tenderness, goiter, inflammatory factors such as erythrocyte sedimentation rate, C-reactive protein increased during 180 days.
Time frame: 180 days
change in thyroid function:from hyperthyroidism on baseline to hypothyroidism after 180 days.
Time frame: 42 days
The Symptom such as anorexia, nausea, vomiting, abdominal pain, fatigue, weakness, collapse, muscle pain, joint pain, weight loss, orthostatic hypotension, lethargy and depression.
Time frame: 42 days
Glucose change when taking medicine:from normal blood glucose on baseline to hyperglycemia at the special time during medication.
Time frame: 42 days
We will measure blood pressure before and after withdraw prednisone in experimental and control group.
Time frame: 42 days
We will measure Bone metabolism markers before and after withdraw prednisone in experimental and control group.
Time frame: 42 days
We will measure Lipids before and after withdraw prednisone in experimental and control group.
Time frame: 42 days
Such as,cushing appearance; female hirsutism, menstrual disorders, impotence in men; gastrointestinal ulcers; psychiatric symptoms: anxiety, agitation, fatigue
Xinqiao Hospital of Chongqing
Other
Efficiency and Safety Study of Short-term Prednisone to Treat Moderate and Severe Subacute Thyroiditis
Acronym: STA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06391515
COVID-19, Coronaviridae Infections
Modena, Italy
View Trial DetailsNCT05070091
Adrenal Gland Diseases, Adrenal Insufficiency
Gdansk, Poland
View Trial DetailsNCT07571681
Autoimmune Diseases, Endocrine System Diseases
View Trial DetailsNCT07652450
Adenocarcinoma, Adenocarcinoma, Follicular
Minya, Minya Governorate, Egypt
View Trial Details